10x Genomics Acquires Proteintech Genomics to Expand Proteomics Capabilities

Why It Matters

Combining protein and RNA analysis deepens cellular insight, positioning 10x as a one‑stop provider of integrated multi‑omics solutions and strengthening its competitive edge in a fast‑growing proteomics market.

Key Takeaways

• 10x adds Proteintech's 347‑antibody panel to its single‑cell suite
• Integration targets higher‑plex proteomics for Atera spatial platform
• Acquisition keeps Proteintech's eight‑person team intact
• Analysts warn near‑term growth may be weighed by Flex Apex costs
• Multi‑omic assays expected to boost 10x's clinical diagnostics roadmap

Pulse Analysis

The integration of Proteintech Genomics into 10x Genomics marks a decisive step toward truly unified multi‑omics workflows. By pairing 10x's scalable single‑cell and spatial sequencing technologies with Proteintech's antibody‑based Human Discovery Panel, researchers can now capture protein expression and transcriptomic data from the same cell in a single, sequencing‑compatible assay. This convergence reduces the need for disparate vendor solutions, shortens experimental timelines, and opens new avenues for high‑resolution cellular phenotyping across biology and drug discovery.

Proteomics is the fastest‑growing segment of the broader $11 billion protein analysis market, projected to expand at double‑digit rates. Industry analysts see higher‑plex protein panels as a key differentiator, yet scaling such assays brings cost and complexity challenges. 10x’s acquisition gives it in‑house expertise to push beyond current plex limits while leveraging its existing Flex Apex and Atera platforms. However, analysts caution that the added R&D spend and integration overhead could pressure near‑term earnings, especially as academic funding tightens.

Financially, the deal had little immediate impact on 10x’s balance sheet, with shares slipping only 0.6% to $29.00 after the announcement. The company reported a Q1 net loss of $13.5 million on $150.8 million revenue, a modest improvement over the prior year. By bolstering its proteomics capabilities, 10x positions itself to capture a larger share of the multi‑omics market and to transition its research tools into clinical diagnostics, a long‑term growth engine. The retained eight‑person Proteintech team ensures continuity, while the expanded assay portfolio could accelerate partnerships and CLIA‑certified test development in oncology, immunology, and neurology.

Deal Summary

10x Genomics announced it has acquired Proteintech Genomics for an undisclosed amount, expanding its proteomics capabilities and multiomics platform. The deal combines 10x’s single‑cell and spatial biology expertise with Proteintech’s antibody‑based protein detection assays, aiming to accelerate higher‑plex proteomics and integrated workflows.